Discussions

Master the critical updates introduced by the New Drugs and Clinical Trials (NDCT) Amendment Rules 2026. Uncover how these progressive regulatory reforms transform the Indian clinical research landscape by optimizing CDSCO approval workflows, simplifying prior intimation pathways for select low-risk studies, and expediting review timelines. Learn strategic compliance adjustments for handling bioequivalence trials, safety reporting mandates, and investigator-initiated studies. Equip your clinical operations and regulatory affairs teams with actionable insights to navigate evolving statutory frameworks, mitigate compliance risks, accelerate product development lifecycles, and ensure seamless market authorization in India's fast-growing pharmaceutical and biotech sector.

read also: zenovel